Intravitreal anti-VEGF drug use in industrialized nations: why are newly introduced medications causing us to inject more and not less?

Click to increase image sizeClick to decrease image size

Notes

Transparency

Declaration of funding

This editorial was not funded.

Declaration of financial/other relationships

M.W.S. has disclosed that he is on the advisory board and receives institutional research support from Allergan and Regeneron, and is a consultant for Boehringer-Ingelheim and Momenta.

CMRO peer reviewer on this manuscript has no relevant financial relationships to disclose.

Notes

1 Ozurdex is a registered trade name of Allergan, Irvine, CA.

2 Iluvien is a registered trade name of Alimera, Alpharetta, GA.